Skip to main content
. 2018 Dec 22;11(1):15. doi: 10.3390/cancers11010015

Table 2.

Ongoing trials of induction chemotherapy in association with immunotherapy.

TRIAL Phase Patients Inclusion Criteria Experimental Treatment
Pich (NCT03114280) I/II 55 Stage III–V oral cavity, oropharynx and hypopharynx) 3 cycles of TPF + Pembrolizumab
NCT03342911 II 37 Stage III–IV oral cavity, oropharynx and hypopharynx) 3 cycles of carboplatin + paclitaxel + Nivolumab
Medinduction (NCT02997332) I 36 Stage III–IV oral cavity, oropharynx and hypopharynx) 3 cycles of TPF + Durvalumab